India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

India's drug regulator has issued a stern warning to pharmaceutical companies. Direct or indirect advertising of weight-loss medicines is now prohibited. Obesity awareness campaigns that promote prescription drugs are also under scrutiny. This move comes as global and domestic companies vie for a share of India's growing obesity drug market. The regulator emphasizes that misleading promotions will face action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qvqk8LB
via IFTTT